alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 12.1**

**Computationof Ratio of Earnings To Fixed Charges**

| ** **                              | ** ** | **Successor Company** | ** ** | **Predecessor Company** | ** ** |
|-----------------------------------------|------------|----------------------------|------------|------------------------------|------------|
| ** **                              | ** ** | ** **                 | ** ** | ** **                   | ** ** | **Period from** | ** ** | **Period from** | ** ** | ** ** | ** ** | ** ** | ** ** |
| ** **                              | ** ** | **Years Ended**       | ** ** | **March 15 to**    | ** ** | **January 1 to** | ** ** | **Years Ended** | ** ** |
| ** **                              | ** ** | **December 31,**      | ** ** | **December 31,**        | ** ** | **March 14,** | ** ** | **December 31,** | ** ** |
| ** **                              | ** ** | **2006**                   | ** ** | **2005**                     | ** ** | **2004** | ** ** | **2004** | ** ** | **2003** | ** ** | **2002** | ** ** |
| Net income (loss)  before income  taxes |       | $                          | (17,046    | )                            | $          | (433 | ) |   | $ | (16,814 | ) |   |   | $ | (12,453 | ) |   | $ | 17,971 |   | $ | 15,244 |   |
| Fixed Charges:                          |       |                       |       |                         |       |   |   |   |   |   |   |   |   |   |   |   |   |
| Interest Expense                        |       | 20,668                     |       | 18,741                       |       |   | 13,597 |   |   |   | 2,513 |   |   | 13,119 |   | 12,402 |   |
| Interest Factor of Operating  Rents     |       | 409                        |       | 356                          |       |   | 271 |   |   |   | 70 |   |   | 334 |   | 290 |   |
| Total Fixed Charges                     |       | $                          | 21,077     |                         | $          | 19,097 |   |   | $ | 13,868 |   |   |   | $ | 2,583 |   |   | $ | 13,453 |   | $ | 12,692 |   |
| Adjusted Earnings                       |       | $                          | 4,031      |                         | $          | 18,664 |   |   | $ | (2,946 | ) |   |   | $ | (9,870 | ) |   | $ | 31,424 |   | $ | 27,936 |   |
| Ratio of Earnings to  Fixed Charges     |       | 0.2                        |       | 1.0                          |       |   | (a | ) |   |   | (a | ) |   | 2.3 |   | 2.2 |   |

----

(a)    Earningsin 2004 were insufficient to cover fixed charges.  The amount of the ratio of earnings to fixedcharges deficiency for the period from March 15 to December 31, 2004 was $2,946and for the period from January 1 to March 14, 2004 was $9,870.

----
I

106TH CONGRESS

1ST SESSION H. R. 1508

To prohibit entry of the Russian vessel KAPITAN MAN into any port

in the United States at which there is a United States naval presence.

IN THE HOUSE OF REPRESENTATIVES

APRIL 21, 1999

Mr. HUNTER introduced the following bill; which was referred to the

Permanent Select Committee on Intelligence

A BILL

To prohibit entry of the Russian vessel KAPITAN MAN

into any port in the United States at which there is

a United States naval presence.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. FINDINGS.

4 The Congress finds the following:

5 (1) United States intelligence reports indicate

6 that vessels of the Far East Shipping Company (a

7 corporation having its principal place of business in

8 Vladivostok, Russia) actively support the Russian

9 military.
2

•HR 1508 IH

1 (2) The Russian merchant vessel KAPITAN

2 MAN (Russian registry number 840 6690) is a ves3 sel in the Far East Shipping Company fleet.

4 (3) During a joint boarding by the United

5 States Customs Service and the Immigration and

6 Naturalization Service in April 1993, the KAPITAN

7 MAN was discovered to have on board devices

8 known as Expendable Bathythermographs. The de9 vices were T7 models, which are manufactured only

10 for United States military use. The sole purpose of

11 the devices is improved sonar prediction in antisub12 marine warfare and other military applications.

13 (4) In April 1994, during an inspection of the

14 KAPITAN MAN by the United States Customs

15 Service and the Immigration and Naturalization

16 Service, sonabuoys were discovered in an obscure

17 compartment that had been sprayed with dog repel18 lent. Such devices are used in the detection of sub19 marines.

20 (5) On April 4, 1997, the KAPITAN MAN was

21 in Puget Sound near Seattle, Washington, when it

22 was photographed from a Canadian military heli23 copter on a routine surveillance mission.

24 (6) United States Navy intelligence officer

25 Lieutenant Jack Daly was on board the helicopter
3

•HR 1508 IH

1 during that mission. Upon returning from the mis2 sion, Lieutenant Daly and the Canadian pilot, Cap3 tain Patrick Barnes, reported injuries that, upon

4 evaluation, were consistent with injuries caused by a

5 laser.

6 (7) Lieutenant Daly and Captain Barnes con7 tinue to suffer severe physical effects from the

8 KAPITAN MAN laser incident.

9 (8) The KAPITAN MAN is suspected by the

10 United States intelligence community of conducting

11 surveillance against United States ballistic missile

12 submarines and aircraft carrier battle groups.

13 SEC. 2. PROHIBITION ON ENTRY OF KAPITAN MAN INTO

14 CERTAIN UNITED STATES PORTS.

15 Notwithstanding any other law, the vessel KAPITAN

16 MAN shall be denied entry to any port in the United

17 States at which there is a United States naval presence.

Æ
Shomari DALEY, petitioner, v. Nancy A. BERRYHILL, Acting Commissioner of Social Security.

No. 18-7559.

Supreme Court of the United States

April 22, 2019.

Petition for rehearing denied.
EXHIBIT 99.1


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Xstream Beverage Group, Inc. (the
"Company") on Form 10-QSB for the period ending June 30, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Steve
A. Haglund, Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of
2002, that to the best of my knowledge and belief:

         a.       The Report fully complies with the requirements of Section
                  13(a) or 15(d) of the Securities Exchange Act of 1934; and

         b.       The information contained in the Report fairly presents, in
                  all material respects, the financial condition and result of
                  operations of the Company.


 /s/ Steve A. Haglund
---------------------------------------------
By: Steve A. Haglund, Chief Executive Officer

Dated: August 13, 2002
Marc SHIROMA, petitioner, v. UNITED STATES.

No. 18-8455.

Supreme Court of the United States

April 15, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
Curtiss WILSON, petitioner, v. HORTON'S TOWING, et al.

No. 18-1081.

Supreme Court of the United States

April 22, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
Lesley Eugene WARREN, petitioner, v. Edward THOMAS, Warden.

No. 18-6588.

Supreme Court of the United States

Feb. 19, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
# Úřední věstník C 516/2021

| | ISSN 1977-0863 |
| --- | --- |
| Úřední věstník
  Evropské unie | C 516 |
| | |
| České vydání | Informace a oznámení | Ročník 6421. prosince 2021 |

ISSN 1977-0863

Úřední věstník

Evropské unie

C 516

České vydání

Informace a oznámení

Ročník 6421. prosince 2021

---

| Obsah | Strana |
| --- | --- |
| | IV   Informace |
| | INFORMACE ORGÁNŮ, INSTITUCÍ A JINÝCH SUBJEKTŮ EVROPSKÉ UNIE |
| | Evropská komise |
| 2021/C 516/01 | Souhrn rozhodnutí Evropské unie o registracích léčivých přípravků do 20. prosince 2021
  (Zveřejněno podle článku 13 nebo článku 38 nařízení Evropského parlamentu a Rady (ES) č. 726/2004) | 1 |

Obsah

Strana

IV   Informace

INFORMACE ORGÁNŮ, INSTITUCÍ A JINÝCH SUBJEKTŮ EVROPSKÉ UNIE

Evropská komise

2021/C 516/01

Souhrn rozhodnutí Evropské unie o registracích léčivých přípravků do 20. prosince 2021
  (Zveřejněno podle článku 13 nebo článku 38 nařízení Evropského parlamentu a Rady (ES) č. 726/2004)

(Zveřejněno podle článku 13 nebo článku 38 nařízení Evropského parlamentu a Rady (ES) č. 726/2004

1

---

| CS | |
| --- | --- |

CS

---

IV Informace

INFORMACE ORGÁNŮ, INSTITUCÍ A JINÝCH SUBJEKTŮ EVROPSKÉ UNIE

Evropská komise

| 21.12.2021 | CS | Úřední věstník Evropské unie | C 516/1 |
| --- | --- | --- | --- |

21.12.2021

CS

Úřední věstník Evropské unie

C 516/1

---

Souhrn rozhodnutí Evropské unie o registracích léčivých přípravků do 20. prosince 2021

(Zveřejněno podle článku 13 nebo článku 38 nařízení Evropského parlamentu a Rady (ES) č. 726/2004 (1))

(2021/C 516/01)

| — | Vydání registrace (článek 13 nařízení Evropského parlamentu a Rady (ES) č. 726/2004): Přijaté













  Datum rozhodnutí | Název léčivého přípravku | INN (mezinárodní nechráněný název) | Držitel rozhodnutí o registraci | Číslo zápisu do rejstříku Společenství | Léková forma | Kód ATC (anatomicko-terapeuticko-chemický kód) | Datum oznámení |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 20.12.2021 | Nuvaxovid | Vakcína proti onemocnění COVID-19 (rekombinantní, obsahující adjuvans) | Novavax CZ, a.s. |
| Bohumil 138, 281 63 Jevany, Česká republika |

—

Vydání registrace (článek 13 nařízení Evropského parlamentu a Rady (ES) č. 726/2004): Přijaté

Datum rozhodnutí

Název léčivého přípravku

INN (mezinárodní nechráněný název)

Držitel rozhodnutí o registraci

Číslo zápisu do rejstříku Společenství

Léková forma

Kód ATC (anatomicko-terapeuticko-chemický kód)

Datum oznámení

20.12.2021

Nuvaxovid

Vakcína proti onemocnění COVID-19 (rekombinantní, obsahující adjuvans)

Novavax CZ, a.s.

Bohumil 138, 281 63 Jevany, Česká republika

EU/1/21/1618

Injekční disperze

J07BX03

20.12.2021

Chcete-li se seznámit s veřejnou zprávou o hodnocení dotyčných léčivých přípravků a se souvisejícími rozhodnutími, obraťte se na:

| European Medicines Agency |
| --- |
| Domenico Scarlattilaan 6 |
| 1083 HS Amsterdam |
| NETHERLANDS |

European Medicines Agency

Domenico Scarlattilaan 6

1083 HS Amsterdam

NETHERLANDS

---

(1)  Úř. věst. L 136, 30.4.2004, s. 1.

---
<TABLE> <S> <C>


       

<ARTICLE> 5
<LEGEND>
THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION  EXTRACTED  FROM  THE
FINANCIAL  STATEMENTS OF BUCKHEAD AMERICA  CORPORATION FOR THE NINE MONTHS ENDED
SEPTEMBER  30,  1996,  AND IS  QUALIFIED  IN ITS  ENTIRETY BY  REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                                 <C>

<PERIOD-TYPE>                       9-MOS
<FISCAL-YEAR-END>                                DEC-31-1996
<PERIOD-START>                                   JAN-01-1996
<PERIOD-END>                                     SEP-30-1996
<CASH>                                                 2,419
<SECURITIES>                                             671
<RECEIVABLES>                                          3,381
<ALLOWANCES>                                           2,249
<INVENTORY>                                                0
<CURRENT-ASSETS>                                       4,500
<PP&E>                                                26,532
<DEPRECIATION>                                         2,160
<TOTAL-ASSETS>                                        32,612
<CURRENT-LIABILITIES>                                  3,496
<BONDS>                                               16,577
<PREFERRED-MANDATORY>                                      0
<PREFERRED>                                                0
<COMMON>                                                  18
<OTHER-SE>                                            11,917
<TOTAL-LIABILITY-AND-EQUITY>                          32,612
<SALES>                                                7,763
<TOTAL-REVENUES>                                      10,168
<CGS>                                                  5,593
<TOTAL-COSTS>                                          6,315
<OTHER-EXPENSES>                                       1,618
<LOSS-PROVISION>                                           0
<INTEREST-EXPENSE>                                     1,144
<INCOME-PRETAX>                                        1,091
<INCOME-TAX>                                               0
<INCOME-CONTINUING>                                    1,091
<DISCONTINUED>                                             0
<EXTRAORDINARY>                                            0
<CHANGES>                                                  0
<NET-INCOME>                                           1,091
<EPS-PRIMARY>                                            .60
<EPS-DILUTED>                                            .60

        

</TABLE>
IIB

106TH CONGRESS

1ST SESSION H. R. 1219

IN THE SENATE OF THE UNITED STATES

AUGUST 3, 1999

Received

AN ACT

To amend the Miller Act, relating to payment protections

for persons providing labor and materials for Federal

construction projects.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,
2

HR 1219 RDS

1 SECTION 1. SHORT TITLE.

2 This Act may be cited as the ‘‘Construction Industry

3 Payment Protection Act of 1999’’.

4 SEC. 2. AMENDMENTS TO THE MILLER ACT.

5 (a) ENHANCEMENT OF PAYMENT BOND PROTEC6 TION.—Subsection (a)(2) of the first section of the Miller

7 Act (40 U.S.C. 270a(a)(2)) is amended by striking the

8 second, third, and fourth sentences and inserting in lieu

9 thereof the following: ‘‘The amount of the payment bond

10 shall be equal to the total amount payable by the terms

11 of the contract unless the contracting officer awarding the

12 contract makes a written determination supported by spe13 cific findings that a payment bond in that amount is im14 practical, in which case the amount of the payment bond

15 shall be set by the contracting officer. In no case shall

16 the amount of the payment bond be less than the amount

17 of the performance bond.’’.

18 (b) MODERNIZATION OF DELIVERY OF NOTICE.—

19 Section 2(a) of the Miller Act (40 U.S.C. 270b(a)) is

20 amended in the last sentence by striking ‘‘mailing the

21 same by registered mail, postage prepaid, in an envelope

22 addressed’’ and inserting ‘‘any means which provides writ23 ten, third-party verification of delivery.’’.

24 (c) NONWAIVER OF RIGHTS.—The second section of

25 the Miller Act (40 U.S.C. 270b) is amended by adding

26 at the end the following new subsection:
3

HR 1219 RDS

1 ‘‘(c) Any waiver of the right to sue on the payment

2 bond required by this Act shall be void unless it is in writ3 ing, signed by the person whose right is waived, and exe4 cuted after such person has first furnished labor or mate5 rial for use in the performance of the contract.’’.

6 SEC. 3. IMPLEMENTATION THROUGH THE GOVERNMENT7 WIDE PROCUREMENT REGULATIONS.

8 (a) PROPOSED REGULATIONS.—Proposed revisions

9 to the Government-wide Federal Acquisition Regulation to

10 implement the amendments made by this Act shall be pub11 lished not later than 120 days after the date of the enact12 ment of this Act and provide not less than 60 days for

13 public comment.

14 (b) FINAL REGULATIONS.—Final regulations shall be

15 published not less than 180 days after the date of the en16 actment of this Act and shall be effective on the date that

17 is 30 days after the date of publication.

Passed the House of Representatives August 2,

1999.

Attest: JEFF TRANDAHL,

Clerk.

By MARTHA C. MORRISON,

Deputy Clerk.
Exhibit 31.1**CERTIFICATION FOR QUARTERLY REPORT ON FORM 10-QSB**I, R.H. Dillon, certify that:1. I have reviewed this report on Form 10-QSB of Diamond Hill Investment Group, Inc.;2. Based on my knowledge, this report does not contain any untrue statement of a material fact oromit to state a material fact necessary to make the statements made, in light of the circumstancesunder which such statements were made, not misleading with respect to the period covered by thisreport;3. Based on my knowledge, the financial statements, and other financial information included inthis report, fairly present in all material respects the financial condition, results of operationsand cash flows of the small business issuer as of, and for, the periods presented in this report;4. The small business issuer’s other certifying officer(s) and I are responsible for establishingand maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and15d-14) for the registrant and have:a) Designed such disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that material information relating tothe small business issuer, including its consolidated subsidiaries, is made known to us by otherswithin those entities, particularly during the period in which this report is being prepared;b) Evaluated the effectiveness of the small business issuer’s disclosure controls and proceduresand presented in this report out conclusions about the effectiveness of the disclosure controls andprocedures, as of the end of the period covered by this report based on such evaluation; andc) Disclosed in this report any change in the small business issuer’s internal control overfinancial reporting that occurred during the small business issuer’s most recent fiscal quarter(the small business issuer’s fourth fiscal quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, the small business issuer’sinternal control over financial reporting; and5. The small business issuer’s other certifying officer(s) and I have disclosed, based on our mostrecent evaluation of internal control over financial reporting, to the small business issuer’sauditors and the audit committee of the small business issuer’s board of directors (or personsperforming the equivalent functions):a) All significant deficiencies and material weaknesses in the design or operation of internalcontrols over financial reporting which are reasonably likely to adversely affect the smallbusiness issuer’s ability to record, process, summarize and report financial information; andb) Any fraud, whether or not material, that involves management or other employees who have asignificant role in the small business issuer’s internal control over financial reporting.        Date: November 14, 2005 /s/R. H. Dillon   R.H. Dillon   Chief Executive Officer  
23
* Pursuant to 5TH CIR. R. 47.5, the court has determined

that this opinion should not be published and is not precedent

except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

June 25, 2003

Charles R. Fulbruge III

Clerk

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 02-21336

Conference Calendar

 

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

ARNULFO AMAYA-SALAZAR,

Defendant-Appellant.

--------------------

Appeal from the United States District Court

for the Southern District of Texas

USDC No. H-02-CR-189-ALL

--------------------

Before DeMOSS, DENNIS, and PRADO, Circuit Judges. 

PER CURIAM:*

 Arnulfo Amaya-Salazar appeals the sentence imposed following

his guilty plea conviction of being found in the United States

after deportation/removal in violation of 8 U.S.C. § 1326. 

Amaya-Salazar contends that 8 U.S.C. § 1326(a) and 8 U.S.C.

§ 1326(b) are unconstitutional. He argues that the prior

conviction that resulted in his increased sentence is an element

of a separate offense under 8 U.S.C. § 1326(b) that should have

been alleged in his indictment. Amaya-Salazar maintains that he
No. 02-21336

-2-

pleaded guilty to an indictment which charged only simple reentry

under 8 U.S.C. § 1326(a). He argues that his sentence exceeds

the maximum term of imprisonment and supervised release which may

be imposed for that offense. 

In Almendarez-Torres v. United States, 523 U.S. 224, 235

(1998), the Supreme Court held that the enhanced penalties in

8 U.S.C. § 1326(b) are sentencing provisions, not elements of

separate offenses. The Court further held that the sentencing

provisions do not violate the Due Process Clause. Id. at 239-47. 

Amaya-Salazar acknowledges that his arguments are foreclosed by

Almendarez-Torres, but asserts that the decision has been cast

into doubt by Apprendi v. New Jersey, 530 U.S. 466, 490 (2000). 

He seeks to preserve his arguments for further review. 

Apprendi did not overrule Almendarez-Torres. See Apprendi,

530 U.S. at 489-90; United States v. Dabeit, 231 F.3d 979, 984

(5th Cir. 2000). This court must follow Almendarez-Torres

“unless and until the Supreme Court itself determines to overrule

it.” Dabeit, 231 F.3d at 984 (internal quotation marks and

citation omitted). The judgment of the district court is

AFFIRMED.

The Government has moved for a summary affirmance in lieu of

filing an appellee’s brief. In its motion, the Government asks

that an appellee’s brief not be required. The motion is GRANTED. 

AFFIRMED; MOTION GRANTED.
Richard Earl SHERE, Jr., petitioner, v. FLORIDA.

No. 18-7568.

Supreme Court of the United States

April 1, 2019.

Petition for writ of certiorari to the Supreme Court of Florida denied.